More Paradigm Biopharmaceuticals Ltd. news
Paradigm Biopharmaceuticals Ltd.ASX: PAR

S&P DJI Announces March 2025 Quarterly Rebalance

Mar 7, 2025 at 6:22 AM EST · Issued by Paradigm Biopharmaceuticals Ltd.

Filed with ASX · Mar 7, 2025 at 6:22 AM EST · 8 pages · English

On 6ix: 6ix.com/news/sandp-dji-announces-march-2025-quarterly-rebalance-85

Paradigm Biopharmaceuticals Ltd. on 6ix

Earlier from Paradigm Biopharmaceuticals

  • Paradigm Secures Ethics Approval for Phase 3 TrialFeb 23, 2025
  • Loyalty and Piggyback Options ProgramJan 31, 2025
  • PAR Selects Advanced Clinical as CRO for Phase 3Jan 30, 2025
  • Quarterly Activities/Appendix 4C Cash Flow ReportJan 30, 2025
  • Paradigm Receives $6.3m R&D Tax RefundJan 23, 2025

Later from Paradigm Biopharmaceuticals

  • March 2025 Quarterly Activities Report & Appendix 4CApr 29, 2025
  • PAR Receives US Ethics Approval for Phase 3May 14, 2025
  • Paradigm Strengthens OA Pipeline with Strategic AcquisitionJun 25, 2025
  • Paradigm Secures US$27M to Advance Phase 3 OA TrialJun 30, 2025
  • June 2025 Quarterly Activities Report & Appendix 4CJul 28, 2025
All Paradigm Biopharmaceuticals news releases↗

Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.

Follow Paradigm Biopharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer